News

CHICAGO, June 1 (Reuters) - Merck is in discussions with various global health authorities about making its COVID antiviral pill molnupiravir ‌available as an Ebola treatment to address the widening outbreak in ‌the Democratic Republic of Congo, a senior executive told Reuters. The outbreak, which has so far infected ​a suspected 1,100 people and resulted in 42 deaths, involves a rare strain of the virus called Bundibugyo for which there are no approved vaccines or treatments.

This year's American Society of Clinical Oncology (ASCO) conference has been a subdued affair for European pharmaceutical companies, with no major plenary presentations and little data capable of moving share prices materially. But beneath the quiet surface, both AstraZeneca PLC (LSE:AZN,...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Safest Dividend Stocks to Buy Right Now. On May 22, 2026, Merck & Co., Inc. (NYSE:MRK) completed a $6 billion underwritten public offering of senior notes across multiple tranches. The issuance carried out under an existing 2010 indenture with U.S. Bank Trust National Association spans […]

Stock Market Today: The Dow Jones index rose Monday amid ongoing hopes for a U.S.-Iran deal. Nvidia stock jumped on a new chip.

AstraZeneca added to its Imfinzi armamentarium on Monday after the immuno-oncology drug led to improved survival in liver cancer patients.

The United States market has experienced a notable upswing, climbing 1.6% in the last week and rising 28% over the past year, with earnings expected to grow by 17% annually. In such an environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on undervalued assets.

Summit said Harmoni-6 is the first Phase 3 study to show a "statistically significant" survival advantage over a PD-1 inhibitor plus chemotherapy.

Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Dividend Paying Stocks to Buy Right Now. Merck & Co., Inc. (NYSE:MRK) is one of the world’s largest healthcare companies, with a portfolio that spans prescription medicines, biologic therapies, vaccines, and animal health products. Yet much of the investment story continues to revolve around […]

The income target is straightforward: $12,500 a month equals $150,000 a year, and the portfolio doing the work is $2.8 million. Dividing the income by the capital gives the math the whole article has to solve: a blended yield of roughly 5.4%. That number falls in the middle of the income-investing spectrum, which is why ... How to Build $12,500 a Month in Dividend Income From a $2.8 Million Portfolio Without Touching the Aggressive Tier

ImmunityBio targets the BCG shortage with new supply deals and label expansion efforts that could strengthen Anktiva demand in bladder cancer.

Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.

Merck bets on newer drugs, pipeline candidates and M&A deals to offset looming Keytruda patent expiry and drive long-term growth.

Merck & Co. has surged past the S&P 500 Index over the past year, and analysts remain somewhat optimistic about the stock’s growth potential.

In May 2026, Exelixis announced extensive upcoming presentations at the ASCO Annual Meeting, highlighting new CABOMETYX data and pivotal zanzalintinib trials across multiple hard-to-treat cancers. These data, alongside a new Merck collaboration on the STELLAR-316 phase 3 colorectal cancer trial using MRD-guided enrollment, underscore Exelixis’ push to extend its oncology footprint beyond CABOMETYX. We’ll now assess how this expanded zanzalintinib program, especially the STELLAR-303 and...

Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

In addition to developing the vaccine for measles, mumps and rubella, Hilleman's pioneering breakthroughs include hepatitis A and B.

The United States market has shown robust performance with a 2.5% increase over the last week and a remarkable 26% rise in the past year, while earnings are projected to grow by 17% annually. In this thriving environment, identifying stocks that may be trading below their estimated value can offer compelling opportunities for investors seeking to capitalize on potential growth at attractive prices.

ABBV's oncology revenues dip 3% in Q1 as Imbruvica sales slide, though Venclexta, Elahere and Epkinly post solid gains.

On May 26, 2026, Micron’s surge helped propel the S&P 500 and Nasdaq to fresh records even as the Dow lagged.

AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.

Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.

The Dow gave back its opening gains, with healthcare stocks a big drag. The blue-chip index was trading flat, while the S&P 500 was up 0.9%, and the Nasdaq rose 1.4%. UnitedHealth Group and Amgen, among the Dow's top five stocks, were down by nearly 3% and 0.4%, respectively.

Wall Street closed higher on Friday, driven by defensive stocks and falling bond yields.

A Minnesota jury has found Merck and several cosmetic talc manufacturers liable in a mesothelioma lawsuit. The verdict centers on claims that Dr. Scholl's-branded talc products were defective and unreasonably dangerous. The case resulted in one of the largest personal injury awards related to cosmetic talc in Minnesota history. For investors watching NYSE:MRK, this verdict introduces a fresh source of legal scrutiny that sits outside the company’s core pharmaceutical and oncology focus. The...

All of them could be "forever" holdings, but the coming decade could prove surprisingly fruitful for each of these outfits.

Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand treatment options.

Gilead wins FDA approval for Hepcludex, the first U.S. therapy for chronic HDV, while Trodelvy advances in Europe for TNBC.

Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares

Go beyond the broad index and find which segment of healthcare best suits your portfolio needs now.